Advertisement
Australia markets close in 5 hours 12 minutes

  • ALL ORDS

    7,419.10
    +13.50 (+0.18%)
     

  • ASX 200

    7,207.40
    +12.50 (+0.17%)
     

  • AUD/USD

    0.6581
    +0.0001 (+0.02%)
     

  • OIL

    71.22
    -0.01 (-0.01%)
     

  • GOLD

    2,022.40
    +7.90 (+0.39%)
     

  • Bitcoin AUD

    66,551.56
    +96.70 (+0.15%)
     

  • CMC Crypto 200

    914.81
    +18.10 (+2.02%)
     

  • AUD/EUR

    0.6110
    -0.0000 (-0.00%)
     

  • AUD/NZD

    1.0737
    -0.0004 (-0.04%)
     

  • NZX 50

    11,485.04
    -10.60 (-0.09%)
     

  • NASDAQ

    16,084.69
    +62.19 (+0.39%)
     

  • FTSE

    7,554.47
    +40.75 (+0.54%)
     

  • Dow Jones

    36,247.87
    +130.47 (+0.36%)
     

  • DAX

    16,759.22
    +130.22 (+0.78%)
     

  • Hang Seng

    16,334.37
    -11.53 (-0.07%)
     

  • NIKKEI 225

    32,307.86
    -550.44 (-1.68%)
     
FEELING THE PINCH? :

Beat the cost-of-living squeeze with our pro tips and helpful hacks - sign up now

Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference

PR Newswire
·2-min read

PONTE VEDRA, Fla., Feb. 6, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive Officer, Quang Pham, is available for one-on-one meetings at the BIO CEO & Investor Conference taking place at the New York Marriott Marquis Times Square on February 6-8, 2023.

Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation. (PRNewsfoto/Cadrenal Therapeutics, Inc.)
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation. (PRNewsfoto/Cadrenal Therapeutics, Inc.)

Meetings with conference attendees can be scheduled through the BIO One-on-One Partnering system: https://www.bio.org/events/bio-ceo-investor-digital-conference/partnering, or by emailing our corporate contacts using the information provided at the end of this press release.

ABOUT CADRENAL THERAPEUTICS, INC.

Cadrenal Therapeutics is focused on developing tecarfarin, a novel cardiorenal therapy with orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to target a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin has been evaluated in eleven human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2 and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com.

For more information, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com

Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700,
CVKD@lythampartners.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-the-2023-bio-ceo--investor-conference-301738951.html

SOURCE Cadrenal Therapeutics, Inc.